Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and earlier mortality. IPF is an age-related disorder, and with the population aging worldwide, the economic burden of...
Idiopathic pulmonary fibrosis (IPF) is a disease marked by progressive scarring of the lungs. The disease is called idiopathic because there is currently no known cause for IPF. Fibrosis, or scar tissue, develops and prevents the lungs from working normally. This gradually interferes with a perso...
Idiopathic Pulmonary FibrosisInterstitial Lung DiseasePharmacotherapyObjectives To discuss the pathophysiological hypotheses of IPF with a view to summarize the data on pharmacological aspects of treatment of this fibrotic Interstitial Lung Disease. Furthermore, the adverse effects are briefly discussed for the...
Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease that develops when the lung tissue becomes scared or fibrotic over time. The scarring progresses differently in everyone, as some people’s disease stays the same for years, and in others, the condition can worsen rapidly. ...
IdiopathicPulmonaryFibrosis;Lungparalysis;TCMclinicalstudy. 特发性肺纤维化;肺痿;中医临床研究。 www.hqzyy.com 5. Idiopathicpulmonaryfibrosisisadiffusepulmonaryfibrosisdisease. 特发性肺纤维化是一种弥漫性的肺纤维化病变。 www.airiti.com 6. Idiopathicpulmonaryfibrosis(IPF) hasapoorprognosisandacoursethat isunpr...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. IPF is more common in elderly patients and over time as healthy lung tissue is replaced by altered extracellular matrix (fibrosis) the alveolar architecture is destroyed, leading to decreased lung function and fin...
Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic pulmonary disease that is characterized by the formation of scar tissue within the lungs in the absence of any known provocation. IPF is a rare disease which affects approximately 5 million persons worldwide. The prevalence is estimated to be...
Learn about Esbriet® (pirfenidone), a medication for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and irreversible fibrotic interstitial lung disease. See full safety for more information.
Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic pulmonary disease that is characterized by the formation of scar tissue within the lungs in the absence of any known provocation. IPF is a rare disease which affects approximately 5 million persons worldwide. The prevalence is estimated to be...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It is associated with increasing cough and dyspnoea and impaired quality of life. IPF affects ∼3 million people ...